SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Tatva Chintan Pharma Chem board approves dividend

05 May 2023 Evaluate
Tatva Chintan Pharma Chem has informed that the Board Recommended a Final Dividend of Rs 2 (20%) per equity share of Rs 10 each fully paid (subject to deduction of tax, if any) on the equity share capital of Rs 22,16,50,620 (2,21,65,062 equity shares of Rs 10 each) for the financial year 2022-23. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.

The above information is a part of company’s filings submitted to BSE.

Tatva Chintan Pharma Share Price

1375.65 53.65 (4.06%)
13-Jul-2026 10:03 View Price Chart
Peers
Company Name CMP
SRF 2756.75
BASF India 3505.00
Pidilite Inds. 1576.90
Tata Chemicals 717.65
Deepak Nitrite 1652.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: